Amgen's Nplate pediatric indication gets FDA approvalAmgen has received the Food and Drug Administration's approval for Nplate for pediatric patients with immune thrombocytopenia. Amgen cuts prices for Repatha devicesAmgen’s Repatha device options, including its prefilled syringe, are being offered at a 60% reduced price of $5,850 per year. Pliaglis’ ‘Not for Home Use’ label restriction gets green lighted Crescita's Pliaglis received approval from the Food and Drug Administration for removal of the "Not for Home Use" label restriction. Braeburn's Brixadi gets tentative approval Braeburn's Brixadi offers treatment for patients with moderate-to-severe opioid use disorder. Sanofi, Merck get Vaxelis approval Sanofi and Merck received the FDA's approval for a new vaccine that will not have a commerical supply available in the United States prior to 2020. Lupin, AbbVie partner to develop cancer drugs Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors. Hikma, Sciecure Pharma ink deal for niche injectable anti-viral medicines Hikma expects its deal with Sciecure will expand its pipeline of niche products. FDA approves new Sprycel indication The Food and Drug Administration has given Bristol-Myers Squibb approval for a new pediatric indication for Sprycel. Stemline Therapeutics gets FDA green light for Elzonris The Food and Drug Administration has approved the first treatment for BPDCN, a rare blood disease. Shire gets FDA’s blessing for Motegrity Shire plans to launch Motegrity for chronic idiopathic constipation in 2019. First Previous 42 43 44 45 46 Next Last